Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 'golden dose' on Mounjaro refers to the dose at which a person's weight loss and side-effect tolerance reach the right balance — typically 5mg, 7.5mg or higher — though the right level is individual, not universal. Many people treat it as a destination, but clinically it is better understood as a decision your prescriber helps you reach over several months of careful titration. Mounjaro (tirzepatide) is a prescription-only medicine, which means a GPhC-registered prescriber assesses your suitability before any dose is changed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The phrase 'golden dose' circulates widely in patient communities and is not a clinical term you will find in the Mounjaro SmPC. In practice it describes the dose point where the medicine is doing its job (measurable weight loss, appetite well controlled) without side effects that make daily life miserable. For some people that landing point is 5mg. For others it is 10mg or 15mg. A small number find 7.5mg is as high as their digestive system comfortably tolerates.
What drives the difference? Partly body weight and metabolism, partly how sensitive your gut is to tirzepatide's gastric-emptying effect, and partly factors your prescriber cannot know until they see how you respond at each step. The golden dose concept is therefore less a target to chase and more a conclusion you and your prescriber reach together, informed by how you felt on the previous pen.
It is worth knowing that the 2.5mg starting pen is calibrated for tolerability, not therapeutic effect. Most of the weight-loss evidence sits at higher doses; the full tirzepatide overview sets out the licensed schedule and the clinical evidence behind it. Getting to 5mg (and beyond) is the direction of travel; how fast depends on you.
Before a dose step upwards, a prescriber reviewing your case is asking several things at once. Are you still experiencing significant nausea from the current dose? Have you given it a full four weeks? Is there measurable progress, however modest? And are there any clinical reasons (certain gut conditions, a history of pancreatitis, medicines that interact) that argue for staying put?
That last point matters. The MHRA's safety guidance on GLP-1 medicines, available at Yellow Card, includes advice on reporting side effects and is worth knowing about before you start titrating upward. Severe or persistent stomach pain that extends to the back is a symptom to take seriously and report to a clinician promptly, it can be a sign of pancreatitis, which is a recognised though infrequent risk with this class of medicines.
The decision is also shaped by what 'good enough' looks like for you personally. If you are losing weight steadily and tolerating 7.5mg without difficulty, there may be no clinical case for pushing to 10mg. Your prescriber is the right person to frame that conversation, not a dose ladder you found online. For a closer look at what the evidence says specifically at the 5mg mark, this page covers the 5mg golden dose in detail.
Titration takes time and routine helps. Injecting on the same day each week (and keeping your pen in the fridge door so it is visible and stays at the correct temperature) makes it easier to build the habit and reduces the chance of a missed dose disrupting your progress. You will find the exact storage window in your Patient Information Leaflet; the eMC SmPC is the definitive reference if you want the technical detail.
During the dose-increase phases, the side effects that are most likely are gastrointestinal: nausea, constipation, loose stools, indigestion. These tend to be most noticeable in the days immediately after a new pen, then settle. Eating smaller portions, avoiding very fatty meals, and staying hydrated makes a real difference for most people. None of that is a substitute for clinical guidance, if symptoms are prolonged or severe, contact your prescriber.
Cost is a practical reality for anyone on private treatment. The Mounjaro price comparison page gives a factual picture of the UK private market, including how dose levels affect monthly cost. What a legitimate private prescription always includes is clinical oversight, the review before each repeat, not just the pen itself.
If you are wondering about the mechanics of making the most of each pen during titration, this guide on getting the most from your Mounjaro pen covers technique and what to check before each injection. And if a 2.5mg starting pen is where you currently are, the 2.5mg golden-dose page addresses the questions that come up most often at that stage.
At nume, no dose moves upward automatically. A named GPhC-registered prescriber reads your case (current weight, side-effect history, any new health information) before confirming a repeat at the same dose or approving a step up. That happens before every order, not just the first.
This is not bureaucracy for its own sake. It is how a responsible prescriber protects you from the most avoidable harms: dose-increasing too fast, missing a contraindication that has changed, or continuing treatment that is not producing the clinical benefit it should. The NHS England guidance on weight-management injections, available at NHS England's medicines-for-obesity pages, describes the clinical oversight that good care looks like, and the same standard applies in the private sector.
If you want to understand the broader treatment options before committing to a next step, the weight-loss treatment overview sets out what is licensed in the UK and how different approaches compare. When you are ready to have your own situation reviewed by a prescriber, you can start a free consultation with our clinical team, there is no obligation, and the review happens the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.